

DAFTAR PUSTAKA

1. World Health Organization (2022). Cancer. Health Topics. 2022. https://www.who.int/health-topics/cancer#tab=tab_1- Diakses Maret 2022.
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394–424.
3. Pangribowo S. Beban Kanker di Indonesia. Pusat Data dan Informasi Kesehatan Kementerian Kesehatan RI. 2019;1–16.
4. Klaassen CD, Watkins JB. Casarett & Doull's Essentials of Toxicology 3rd ed. New York: McGraw Hill Professional; 2015.
5. Rasjidi I. Buku Ajar Onkologi Klinik. Jakarta: EGC; 2013. p.187
6. Ryu M, Hwang JI. Cancer site differences in the health-related quality of life of Korean cancer survivors: Results from a Population-based Survey. *Public Health Nurs.* 2019;36(2):144–154.
7. Lukman G, Harjanto E. Tata Laksana Farmakologis Nyeri Kanker. *Indonesian Journal Of Cancer.* 2007;3:121–123.
8. Batalini F, Gomes M, I F, Kuwae F, Macanhan G, Pereira JLB. Cancer complaints: The profile of patients from the emergency department of a Brazilian oncology teaching hospital. *F1000Research.* 2017;6:1919
9. Mahmud, Wisudarti CFR, Nugraha AF. Penatalaksanaan paliatif pasien dengan nyeri kanker. *J Komplikasi Anestesi.* 2016;4(80):87–98.
10. Suwondo BS, Meliala L, Sudadi. Buku Ajar Nyeri. Yogyakarta : Perkumpulan Nyeri Indonesia; 2017. p.506
11. Jensen MP, Tome-Pires C, delaVega R, Galan S, Sole E, Miro J. What determine whether a pain is rated as mild, moderate, or severe? The importance of pain beliefs and pain interference. *Clin J Pain.* 2017;33(5):414–421.
12. Lin J, Hsieh RK, Chen JS, Lee K Der, Rau KM, Shao YY, et al. Satisfaction with pain management and impact of pain on quality of life in cancer patients. *Asia Pac J Clin Oncol.* 2020;16(2):91–98.
13. Yang J, Bauer BA, Wahner-Roedler DL, Chon TY, Xiao L. The modified WHO analgesic ladder: Is it appropriate for chronic non-cancer pain? *J Pain Res.* 2020;13:411–417.

14. Wetan NGAAMY. Tantangan dalam manajemen kronis. In: Management of soft tissue sarcoma : Where Are We? and Breast Cancer Hormonal And Targeted Therapy. Bali : PT. Percetakan Bali; 2017. p.51
15. Van den beuken-Van everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. *J Pain Symptom Manage* 2016;51(6):1070-1090.
16. Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. *Cochrane Database Syst Rev*. 2016;(4):1-101.
17. Heri AAP, Subarnas A. Morfin : Penggunaan Klinis dan Aspek-Aspeknya. *Farmaka*. 2020;17(1):213–221.
18. Riley J, Ross JR, Rutter D, Wells AU, Goller K, Du Bois R, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. *Support Care Cancer*. 2006;14(1):56–64.
19. Wisanti NO. Studi Penggunaan analgesik morfin pada pasien kanker payudara di Instalasi Paliatif dan Bebas Nyeri RSUD Dr. Soetomo Surabaya. Universitas Airlangga; 2016.
20. Mellon RD, Bayer BM. Evidence for central opioid receptors in the immunomodulatory effects of morphine: Review of potential mechanisms of action. *J Neuroimmunology*. 1998;83(1–2):19–28.
21. Lutfy K, Cowan A. Buprenorphine pharmacology. *Current Neuropharmacology*. 2004;2(4):395–402.
22. Corli O, Floriani I, Roberto A, Montanari M, Galli F, Greco MT, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? a multicenter randomized phase IV ‘real life’ trial on the variability of response to opioids. *Annual Oncology*. 2016;27(6):1107–1115.
23. Nosek K, Leppert W, Nosek H, Wordliczek J, Onichimowski D. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. *Drug Design Development Therapy*. 2017;11:2409–2419.
24. Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. *J Clinical Oncology*. 2004;22(1):185–192.
25. Guo KK, Deng CQ, Lu GJ, Zhao GL. Comparison of analgesic effect of oxycodone and morphine on patients with moderate and advanced cancer pain: a meta-analysis. *BMC Anesthesiology*. 2018;18(1):1–9.

26. Wang YM, Liu ZW, Liu JL, Zhang L. Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: A meta-analysis of randomized controlled trials. *Experimental Therapeutic Medicine*. 2012;4(2):249–254.
27. Zhou J, Wang Y, Jiang G. Oxycodone versus morphine for cancer pain titration: A systematic review and pharmacoeconomic evaluation. *PLoS One*. 2020;15(4):1–19.
28. Kinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M. Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone. *Clin Pharmacokinet*. 2019 Jun;58(6):705-725
29. Kalso E. Oxycodone. *J Pain Symptom Management*. 2005;29(5):47–56.
30. Guo KK, Deng CQ, Lu GJ, Zhao GL. Correction to: Comparison of analgesic effect of oxycodone and morphine on patients with moderate and advanced cancer pain: A meta-analysis. *BMC Anesthesiology*. 2018;18:173
31. Suzuki M, Sakurada T, Gotoh K, Watanabe S, Satoh N. Correlation between the administration of morphine or oxycodone and the development of infections in patients With cancer pain. *American J Hospice Palliative Medicine*. 2013;30(7):712–716.
32. Dorland. *Kamus saku kedokteran dorland 31st ed*. Singapore; 2011.
33. World Health Organization. Cancer. Fact Sheets Newsroom. 2022. <https://www.who.int/news-room/fact-sheets/detail/cancer> diakses Februari 2023
34. Hanahan D. Hallmarks of Cancer: New Dimensions. *Cancer Discov*. 2022;12(1):31–46.
35. Das S, Kundu M, Jena BC, Mandal M. Causes of cancer: Physical, chemical, biological carcinogens, and viruses. *Biomaterials for 3D Tumor Modeling*. 2020: 607–641.
36. Nath G, Gulati AK, Shukla VK. Role of bacteria in carcinogenesis, with special reference to carcinoma of the gallbladder. *World J Gastroenterol*. 2010;16(43):5395–5404.
37. Wonid J, Cho Y, Lee D, Jeon BY, Ju JW, Chung S, et al. Clonorchis sinensis excretory-secretory products increase malignant characteristics of cholangiocarcinoma cells in three-dimensional co-culture with biliary ductal plates. *PLoS Pathog*. 2019;15(5):1–19.
38. Bennett MI, Kaasa S, Barke A, Korwisi B, Rief W, Treede RD. The IASP classification of chronic pain for ICD-11: Chronic cancer-related pain. *Pain*. 2019;160(1):38–44.

39. Elhassan MMA, Taha SIH, Maatoug MMA. Unplanned attendances of cancer patients to an outpatient unit in a low-income country: A prospective study from Sudan. *South African J Oncology*. 2020;4:1–8.
40. Bruera E, Sweeney C. Cachexia and asthenia in cancer patients. *Lancet Oncology*. 2000;1(3):138–147.
41. Silva SPD, Santos JMO, Silva MPCE, Costa RMGD, Medeiros R. Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia. *J Cachexia Sarcopenia Muscle*. 2020;11(3):619–635.
42. Barón MG, Feyjóo M, Carulla Torrent J, Camps C, Escobar Y, Belda-Iniesta C. Study of the prevalence of tumour-related asthenia in Spanish cancer patients. *Clin Transl Oncol*. 2008;10(6):351–358.
43. Pasikhova Y, Ludlow S, Baluch A. Fever in patients with cancer. *Cancer Control*. 2017;24(2):193–197.
44. Foggo V, Cavenagh J. Malignant causes of fever of unknown origin. *Clin Med J R Coll Physicians London*. 2015;15(3):292–294.
45. Lohr L. Chemotherapy-induced nausea and vomiting. *Cancer J*. 2008;14(2):85–93.
46. IASP. Nociceptive Pain . International association for the study of pain. 2011. <https://www.iasp-pain.org/resources/terminology> - Diakses 2022
47. Asif N, Hassan K. Clinical Manifestations of Acute Myeloid Leukemia. *J Islam Med Dent Coll*. 2007;1211(1):6–9.
48. Dewi DAK, Wiratnaya GE, Setiawan GB. Prevalensi metastatic bone disease (MBD) berdasarkan umur, lokasi, dan tumor primer di RSUP Sanglah/ FK Unud Periode 2013-2017. *SMF Ortopedi dan Traumatol*. 2019;8(8).
49. Christian-Miller N, Frenette C. Hepatocellular cancer pain: impact and management challenges. *J Hepatocellular Carcinoma*. 2018;5:75–80.
50. IASP. Neuropathic Pain . International association for the study of pain. 2011. Available from: <https://www.iasp-pain.org/resources/terminology>- Diakses 2022
51. Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S. Prevalence and aetiology of neuropathic pain in cancer patients: A systematic review. *Pain* . 2012;153(2):359–365.
52. Kresnodi E. Pengelolaan Nyeri Kanker. *J Kedokteran*. 2012;1(1):41–56.
53. Freynhagen R, Parada HA, Calderon-Ospina CA, Chen J, Rakhmawati Emril D,

- Fernández-Villacorta FJ, et al. Current understanding of the mixed pain concept: a brief narrative review. *Curr Med Res Opin.* 2019;35(6):1011–1018.
54. AC, Guyton. Hall J. *TextBook of Medical Physiology* 12th ed. United States of America: Elsevier; 2006. p.598–605.
 55. Esin E, Yalcin S. Neuropathic cancer pain: What we are dealing with? How to manage it? *Onco Targets Therapy.* 2014;7:599–618.
 56. Prof Darwin, Saraf P. *Patofisiologi Nyeri Neuropatik.* Pain.
 57. Meliala L. Nyeri neuropatik : mekanisme simptom. *Berkala Neuro Sains.* 2001;2:255–260.
 58. Latremoliere A, Woolf CJ. Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural Plasticity. *J Pain.* 2009;10(9):895–926.
 59. Chang KH, Ro LS. Neuropathic pain: Mechanisms and treatments. *Chang Gung Med J.* 2005;28(9):597–605.
 60. Takeda M, Matsumoto S. Peripheral and Central Mechanisms of Mechanical Allodynia: Neurokinin Receptor for Therapeutic Target. *Cent Nerv Syst Agents Med Chem.* 2008;6(4):311–20.
 61. Jaatun EAA, Haugen DF, Dahl Y, Kofod-Petersen A. Proceed with caution: Transition from paper to computerized pain body maps. *Procedia Comput Sci.* 2013;21(1):398–406.
 62. Caraceni A, Shkodra M. Cancer pain assessment and classification. *Cancers (Basel).* 2019;11(4).
 63. World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization. 2018.
 64. Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, et al. Adult cancer pain, version 3. *JNCCN J Natl Comprehensive Cancer Network.* 2019;17(8):977–1007.
 65. Lugo R, Kern S. Clinical Pharmacokinetics of Morphine. *J Pain Palliat Care Pharmacotherapy.* 2002;16(4):5–18.
 66. Pathan H, Williams J. Basic opioid pharmacology : an update. *British Journal of Pain.* 2012;6(1):11-16.
 67. Law PY, Wong Y, Loh H. Molecular Regulation of a Dipogenesis. *Annual Review Cell Development Biology.* 2000;16(1):145–171.
 68. Green BN. Writing narrative literature reviews for peer reviewed journals:

- secrets of the trade. *J Chiropractic Med.* 2006;5(3):101–17.
69. National Center for Biotechnology Information. Neoplasm. MesH Database. <https://www.ncbi.nlm.nih.gov/mesh/68009369>_ Diakses Januari 2021
 70. Riley J, Eisenberg E, Müller-Schwefe G, Drewes AM, Arendt-Nielsen L. Oxycodone: A review of its use in the management of pain. *Curr Med Res Opin.* 2008;24(1):175–192.
 71. Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. *Support Care Cancer.* 2003;11(2):84–92.
 72. National Center for Biotechnology Information. Pain. MesH Database. <https://www.ncbi.nlm.nih.gov/mesh/68010146>- Diakses Januari 2021.
 73. National Center for Biotechnology Information (2008). Clinical trial. Mesh Database. <https://www.ncbi.nlm.nih.gov/mesh/68016430>- Diakses Januari 2021
 74. National Center for Biotechnology Information (2008). Randomized controlled trial. Mesh Database. <https://www.ncbi.nlm.nih.gov/mesh/68016449>- Diakses Januari 2021
 75. National Center for Biotechnology Information (2008). Review. MesH Database. <https://www.ncbi.nlm.nih.gov/mesh/68016454>- Diakses Januari 2021
 76. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ.* 2009;339.
 77. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. *JAMA Oncol.* 2019;5(12):1749–1768.
 78. Scarborough BM, Smith CB. Optimal pain management for patients with cancer in the modern era. *CA Cancer J Clin.* 2018;68(3):182–196.
 79. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. *Palliat Med.* 2011;25(5):402–409.
 80. Poliwoda S, Noor N, Jenkins JS, Stark CW, Steib M, Hasoon J, et al. Buprenorphine and its formulations: a comprehensive review. *Heal Psychol Res.* 2022;10(3):1–10.

81. Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal soluble film. *Pain Med.* 2010;11(7):1017–1023.
82. Lötsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G. Pharmacokinetics of non-intravenous formulations of fentanyl. *Clin Pharmacokinet.* 2013;52(1):23–36.
83. Yoshimoto T, Ryu E, Tomiyasu S, Hojo M, Kokubun H, Matoba M. Efficacy and safety of oxycodone injection for relieving cancer pain: A study in Japan consisting of two open trials for intravenous and subcutaneous administration. *Biol Pharm Bull.* 2018;41(6):850–857.
84. Lee KH, Kang JH, Oh HS, Choi MK, Shim BY, Eum YJ, et al. Intravenous oxycodone versus intravenous morphine in cancer pain: A randomized, open-label, parallel-group, active-control study. *Pain Res Management.* 2017.
85. Pan H, Shen P, Shu Q, Lu L, Qian S, Zhou Y, et al. Efficacy and safety of sustained-release oxycodone compared with immediate-release morphine for pain titration in cancer patients: A multicenter, open-label, randomized controlled trial (social). *Med United States.* 2019;98(24).
86. Riley J, Branford R, Droney J, Gretton S, Sato H, Kennett A, et al. Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial. *J Pain Symptom Management.* 2015;49(2):161–172.
87. Ritonga AH, Solihat Y, Veronica A. perbedaan pengaruh morphin controlled release 30 mg dan oxycodone controlled release 20 mg oral terhadap nyeri kanker. *J Anestesi Perioperatif.* 2017;5(3):192–197.
88. Zecca E, Brunelli C, Bracchi P, Biancofiore G, De Sangro C, Bortolussi R, et al. Comparison of the tolerability profile of controlled-release oral morphine and oxycodone for cancer pain treatment. An open-label randomized controlled trial. *J Pain Symptom Management.* 2016;52(6):783–794.
89. Mercadante S, Tirelli W, David F, Arcara C, Fulfarò F, Casuccio A, et al. Morphine versus oxycodone in pancreatic cancer pain: A randomized controlled study. *Clin J Pain.* 2010;26(9):794–797.
90. Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. *J Clin Oncology.* 1998;16(10):3222–3229.
91. King SA. CDC guideline for prescribing opioids for chronic pain. *Psychiatry Times.* 2016;33(6).
92. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: Evidence-based

recommendations from the EAPC. *Lancet Oncology*. 2012;13(2):58–68.

93. Mercadante S, Adille C, Cascio AL CA. Rapid titration with intravenous oxycodone for severe cancer pain and oral conversion ratio. *J Pain Symptom Manag*. 2022;64(6):532–536.
94. Hanks GW, Conno F de, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. Morphine and alternative opioids in cancer pain: The EAPC recommendations. *Br J Cancer*. 2001;84(5):587–593.

